论文部分内容阅读
目的对转移性结直肠癌患者接受mFOLFOX-6方案与FOLFILI方案治疗的疗效以及不良反应进行观察分析。方法 50例转移性结直肠癌患者作为本次研究对象,根据患者治疗方案的不同分为实验组及对照组,各25例。实验组接受mFOLFOX-6方案治疗,对照组接受FOLFILI方案治疗。对比两组患者的疗效以及不良反应发生情况。结果治疗后,实验组患者的总有效率为40.00%、控制率为84.00%,对照组患者的总有效率为40.00%、控制率为80.00%,两组对比差异均无统计学意义(P>0.05)。实验组外周神经毒性发生率84.00%高于对照组的32.00%,延迟性腹泻发生率16.00%、胆碱能综合征发生率0均低于对照组的44.00%、24.00%,差异均具有统计学意义(P<0.05)。实验组和对照组的骨髓抑制发生率(80.00%、72.00%)对比差异无统计学意义(P>0.05)。结论转移性结直肠癌患者接受mFOLFOX-6方案与FOLFILI方案进行治疗,均可取得较好的效果,两种治疗方案均可导致患者出现不良反应情况,其中mFOLFOX-6方案治疗的主要不良反应为外周神经毒性,FOLFILI方案治疗的主要不良反应为胆碱能神经综合征与延迟性腹泻,临床可根据转移性直肠癌患者的具体病情以及耐受情况,为其选择合理的方案进行治疗。
Objective To investigate the curative effect and side effects of mFOLFOX-6 regimen and FOLFILI regimen in patients with metastatic colorectal cancer. Methods Fifty patients with metastatic colorectal cancer were divided into experimental group and control group according to the different treatment plans of patients. The experimental group received mFOLFOX-6 regimen and the control group received FOLFILI regimen. The curative effect and adverse reaction of two groups were compared. Results After treatment, the total effective rate was 40.00% in the experimental group and the control rate was 84.00%. The total effective rate in the control group was 40.00% and the control rate was 80.00%. There was no significant difference between the two groups (P> 0.05). The incidence of peripheral neurotoxicity in experimental group was 84.00% higher than that in control group, 32.00% in control group, the incidence of delayed diarrhea was 16.00%, and the incidence of cholinergic syndrome in control group was lower than 44.00% and 24.00% in control group Significance (P <0.05). There was no significant difference in the incidence of bone marrow suppression (80.00%, 72.00%) between the experimental group and the control group (P> 0.05). Conclusion Both mFOLFOX-6 regimen and FOLFILI regimen are effective in patients with metastatic colorectal cancer, both of which can lead to adverse reactions. The main side effects of mFOLFOX-6 regimen are Peripheral neurotoxicity, FOLFILI regimen treatment of major adverse reactions for cholinergic syndrome and delayed diarrhea, clinically based on the specific conditions of metastatic colorectal cancer patients and tolerance, for the selection of a reasonable program for treatment.